FDA evaluates EUA bids for J&J's Janssen and Bharat BioTech's Covaxin

The Food and Drug Administration (FDA) is evaluating two pending applications for emergency use authorization (EUA) of COVID-19 vaccines: Johnson & Johnson's Janssen vaccine and Bharat BioTech's Covaxin.

Bharat BioTech still lacks necessary requirements, particularly certification from the inspecting body regarding good manufacturing practices.

The Philippines' evaluation of Johnson & Johnson’s application will also consider reports of rare blood clots among individuals abroad who received the vaccine, as highlighted by Health Undersecretary Maria Rosario Vergeire.